Pharmacogenetic-Guided Antidepressant Prescribing in Adolescents With Anxiety and Depression
Recruiting · NCT06853587 · Interventional (participants receive a specific treatment) · Lead sponsor: University of Calgary
View the official record on ClinicalTrials.gov →Interventions studied
Current prescribing guidelines/recommendationsPharmacogenetic-guided dosing
What this trial is about
This is a parallel arm randomized (1:1) controlled trial. Adolescents aged 12-17 years (n=228) who are starting or changing a selective serotonin reuptake inhibitor (SSRI) for depression and/or anxiety will be randomly allocated to receive 12-weeks of pharmacogenetic-guided antidepressant therapy (experimental intervention) or current prescribing guidelines/recommendations guided therapy (control intervention).
Who can take part
Age range
12 Years to 17 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Age 12-17
- Depression and/or anxiety as the primary concern, confirmed by the treating physician
- Intention to start a new SSRI
- English fluency
Exclusion criteria
- Co-occurring obsessive compulsive disorder, psychosis, bipolar disorder, eating disorder, autism spectrum disorder, fetal alcohol spectrum disorder, or intellectual disability
- History of non-response to 3 or more SSRI medications as confirmed by the treating physician
- Brain stimulation-based therapy initiated within 8 weeks of referral, or plans to initiate/change brain stimulation during study participation
- History of liver or hematopoietic cell transplant
- History of CYP2B6, CYP2C19, or CYP2D6 testing
Where it is running
1 location listed.
- University of Calgary - Calgary, Alberta, Canada